Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Anti-TAG-72 Monoclonal Antibody CC49-Streptavidin Conjugate | NCIT_C93264 | [An immunoconjugate containing CC49, a monoclonal antibody (MAb) directed against the tumor-associated antigen (TAA) tumor-associated glycoprotein 72 (TAG-72), conjugated to streptavidin, a nonglycosylated homotetrameric protein that has four high affinity binding sites for biotin, with potential use in pre-targeted radioimmunotherapy (PRIT). Upon administration of anti-TAG-72 MAb CC49-streptavidin conjugate, the MAb moiety targets and binds to TAG-72 expressed on cancer cells. Upon subsequent administration of a biotin-based radioconjugate, such as yttrium Y 90 DOTA-biotin, the biotin moiety of the radioconjugate binds to the streptavidin moiety of MAb CC49-streptavidin conjugate, which localizes the biotin-conjugated radionuclide to the tumor site. Upon cellular internalization, a cytotoxic does of radiation may be specifically delivered to TAG-72-expressing tumor cells. TAG-72, a human pancarcinoma antigen, is overexpressed on a variety of cancer cell types.] |
| Strontium Ranelate | NCIT_C93265 | |
| Bone Resorption Inhibitor | NCIT_C67439 | |
| Agglutinin | NCIT_C93266 | |
| Chitinase-3-Like Protein 1 | NCIT_C93267 | [Chitinase-3-like protein 1 (383 aa, ~43 kDa) is encoded by the human CHI3L1 gene. This protein plays a role in tissue remodeling, inflammation and chitin binding.] |
| Rhabdoid Tumor Predisposition Syndrome | NCIT_C93268 | [A neoplastic syndrome most often caused by mutations in the hSNF5/INI1 tumor suppressor gene. It is characterized by the development of an atypical teratoid/rhabdoid tumor in infancy and early childhood. This highly aggressive tumor develops in the central nervous system as an isolated lesion or in combination with extrarenal or renal rhabdoid tumor. Patients may also develop other central nervous system malignancies including medulloblastoma, supratentorial primitive neuroectodermal tumor, and choroid plexus carcinoma.] |
| Bulk-forming Agent | NCIT_C93269 | |
| Pro-oxidant | NCIT_C93260 | |
| Chemical Modifier | NCIT_C1932 | [A chemical that influences the properties of another chemical or biological function. (NCI)] |
| Lobeline | NCIT_C93261 | |
| Nicotinic Agonist | NCIT_C73579 | [Natural or synthetic compounds mimicking acetylcholine neurotransmitter action at nicotinic receptors, which are ionotropic receptors that form ligand-gated ion channels in plasma membranes.] |
| Arctigenin | NCIT_C93251 | |
| Sesquiterpene Lactone | NCIT_C93252 | |
| Cnicin | NCIT_C93253 | |
| Regenerative Medicine | NCIT_C93254 | [The branch of medicine that involves the laboratory growth of functional tissues and organs and their use to regenerate or replace tissues and organs in the body that are damaged by diseases or cannot be healed. Examples include the transplantation of in vitro developed tissues, cell therapies, and stimulation of regeneration by biological substances.] |
| Medicine | NCIT_C16833 | [The branches of medical science that deal with nonsurgical techniques.] |
| Autoclave-resistant Factor | NCIT_C93255 | |
| Transfer Factor | NCIT_C93256 | |
| Calendula Ointment | NCIT_C93257 | |
| Rapid-onset Opioid | NCIT_C93258 |